Celgene Higher Off Positive Phase II Sunbeam Trial Of Oral Ozanimod
Celgene Corporation (NASDAQ: CELG) shares are trading higher by $2.00 at $120.66 in Friday's session. The catalyst for the rally is a Phase II study of Oral Ozanimod with relapsing MS meeting its primary endpoint in reducing ARR, measured endpoints.
After a higher open, it had a brief retreat but found found support just under above Thursday's close ($118.66), only reaching $118.81 before continuing its move higher.
So far, the ensuing rally has cleared the pair of highs from Wednesday ($120.63) and Thursday ($120.77), reaching $120.90. If the rally continues, the next resistance daily resistance point comes in at its January 19 high of $121.59.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.